Doxorubicin Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast by 2031

The doxorubicin market size is projected to reach US$ 2.35 billion by 2031 from US$ 1.47 billion in 2023. The market is expected to register a CAGR of 6.1% during 2023–2031. The increasing approval of generic products is likely to remain a key trend in the doxorubicin market.

Doxorubicin Market Analysis

Factors such as increasing preference for chemotherapy and rising prevalence of cancer are driving the market growth. Moreover, the increasing government funding, guidance, and technical assistance for cancer prevention is providing significant opportunities for the future growth of the doxorubicin market players.

Doxorubicin Market Overview

Doxorubicin is used in chemotherapy to treat a different type of cancers, including bladder cancer, breast cancer, lymphoma, and other. It is injected intravenously alongside other chemotherapy medicines and is marketed under various brand names, including Adriamycin and Caelyx, among others. Adriamycin is a popular anthracycline chemotherapy medication that inhibits the development of cancer cells.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Doxorubicin Market: Strategic Insights

Doxorubicin Market

• 
  CAGR (2023 - 2031)

  6.1%
• Market Size 2023
  US$ 1.47 Billion
• Market Size 2031
  US$ 2.35 Billion

Market Dynamics

GROWTH DRIVERS

• Increasing Prevalence of Cancer
• Increasing Preference for Chemotherapy

FUTURE TRENDS

• Introduction of Nanaomaterials in Cancer Treatment is the New Trends Witnessed in the Market

OPPORTUNITIES

• Increasing Government Funding and Grants

Key Players

• Accord Healthcare
• Cipla Inc
• Dr Reddy s Laboratories
• Meiji Holdings Co Ltd
• Janssen Pharmaceuticals Johnson and Johnson Services Inc
• Novartis AG
• Pfizer Inc
• Sun Pharmaceutical Industries Ltd
• Baxter International Inc
• Zydus Cadila

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Drug Formulation

• Lyophilized Powder
• Doxorubicin Injection

Application

• Breast Cancer
• Kidney Cancer
• Liver Cancer
• Sarcoma
• Ovarian Cancer
• Lung Cancer
• Leukemia
• Multiple Myeloma

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Doxorubicin Market Drivers and Opportunities

Increasing Preference for Chemotherapy Favors Market Growth

Spending on anticancer drugs is essential to incurring excess healthcare costs. Both targeted therapy and chemotherapy significantly improve cancer patient's chances of survival. These therapies may bring about the complete reduction of a tumor. The demand for chemotherapy has surged globally, owing to the benefits. According to an article published in Lancet Oncology, the number of patients requiring chemotherapy will rise by 53% from 2018 to 2040. Advanced cancer treatments improve patient survival and increase long-term outpatient chemotherapy requirements. More exposure to chemotherapy results in a greater demand for doxorubicin drugs, thereby boosting the market growth.

Increasing Government Funding and Grants to Create Notable Opportunities in Future

Many programs have started by various countries for effective and rapid treatment for cancer. For instance, in June 2020, the University of Missouri School of Medicine received  a grant of nearly US$ 3.5 million from the National Institutes of Health to study a pre-treatment for chemotherapy that might protect the patients of cancer suffering from therapy-induced heart complications. Thus, increasing government support as grants and assistance are supporting significant growth opportunities for the doxorubicin drug manufacturers.

Doxorubicin Market Report Segmentation Analysis

Key segments that contributed to the derivation of the doxorubicin market analysis are drug formulation, application and distribution channel.

• By drug formulation, the market is bifurcated into lyophilized powder and doxorubicin injection. In 2023, the lyophilized powder segment held a larger share of the market.
• Based on application, the doxorubicin market is segmented into lung cancer, sarcoma, breast cancer, multiple myeloma, ovarian cancer, kidney cancer, leukemia, liver cancer, and others. In 2023, the breast cancer segment held the largest share of the market. The kidney cancer segment is estimated to register the highest CAGR during the forecast period.
• In terms of distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held a significant share of the market in 2023.

Doxorubicin Market Share Analysis by Geography

The geographic scope of the doxorubicin market report encompasses five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America dominated the doxorubicin market in 2023. The continuous growth in the pharmaceutical industry, rising prevalence of various cancers, and increasing R&D initiatives by the key players are the driving factors for the doxorubicin market in North America, which are propelling the market's expansion in this region.

Doxorubicin Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Doxorubicin Market News and Recent Developments

The doxorubicin market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the market are mentioned below:

• Zydus Cadila has received final approval from the USFDA to market Doxorubicin Hydrochloride Liposome Injection (US RLD: Doxil Liposome Injection) in the strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. (f Zydus Cadila, Press Release, September 2020)

Doxorubicin Market Report Coverage and Deliverables

The “Doxorubicin Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:

• Root canal market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Root canal market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Root canal market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the doxorubicin market
• Detailed company profiles